Singapore’s Parliament has approved legislation that will consolidate additional health-regulatory functions under the Health Sciences Authority. The parliamentary bills register records the Health Sciences Authority (Amendment) and Other Matters Bill as receiving its Second Reading and being passed on 8 September 2026, while the Ministry of Health published its announcement on 9 September. The parliamentary record has been used here as the authoritative source for the passage date.

HSA currently regulates health products including medicines and medical devices, while the Ministry of Health administers areas such as healthcare services, health information, human biomedical research and biosafety. A separate secretariat supports the professional boards and councils responsible for healthcare professionals. The legislation provides the foundation for bringing these functions under a more integrated regulatory structure.

Expanded Functions for HSA

The legislation expands HSA’s responsibilities to include regulatory functions currently administered under the Human Biomedical Research Act and the Biological Agents and Toxins Act. It also enables HSA officers to exercise functions connected with specified Ministry of Health legislation.

The Biological Agents and Toxins Act regulates the possession, use, import, transhipment, transfer and transportation of scheduled biological agents and toxins. Its Fifth Schedule includes botulinum toxins, Clostridium perfringens toxins, staphylococcal enterotoxins, Shiga toxins and verotoxins. The Bill changes which authority administers these responsibilities but does not itself introduce new substance listings or amend the existing schedules.

Phased Implementation

The restructuring will be implemented in two phases. Ministry of Health regulatory functions and personnel are scheduled to transfer to HSA in November 2026, while the functions and personnel of the Secretariat of Healthcare Professional Boards are expected to transfer by the end of 2027.

The Act will commence on a date or dates appointed by the responsible minister. Consequently, passage of the Bill should not be interpreted as an immediate transfer of every regulatory function or as an immediate amendment to existing health-product registration, licensing, labelling or reporting requirements.

Practical Significance

For pharmaceutical and medical-device companies, the development is initially an institutional and administrative change rather than a new product-compliance regime. Existing approvals, licences and regulatory requirements continue to apply unless HSA or the Ministry of Health issues separate transition instructions.

The consolidated structure is intended to provide clearer and more coordinated regulatory engagement for technologies that cross traditional regulatory boundaries. This may be particularly relevant to AI-enabled medical devices, diagnostics, genomics, clinical research and products involving both health-product and biomedical-research requirements.

Companies should monitor transition guidance before the first transfer begins in November. Regulatory contacts, application portals and responsibility for particular submissions may change as functions move to HSA, but businesses should not alter established compliance procedures until official operational instructions are issued.